Suzanne Merrill, MD, on recent progress with immunotherapy in bladder cancer

In a recent interview with Urology Times®, Suzanne B. Merrill, MD, FACS, shared key takeaways from her session at the 2025 LUGPA Annual Meeting titled, “Recent updates in immunotherapy in bladder cancer.” Specifically, Merrill highlighted the phase 3 CREST and POTOMAC trials in non-muscle invasive bladder cancer (NMIBC), as well as the NIAGARA and KEYNOTE-905/EV-303 trials in muscle-invasive bladder cancer (MIBC).

Merrill is a urologic oncologist at Colorado Urology.